ES2582646T3 - Formulación de comprimido recubierto y método - Google Patents
Formulación de comprimido recubierto y método Download PDFInfo
- Publication number
- ES2582646T3 ES2582646T3 ES05756474.2T ES05756474T ES2582646T3 ES 2582646 T3 ES2582646 T3 ES 2582646T3 ES 05756474 T ES05756474 T ES 05756474T ES 2582646 T3 ES2582646 T3 ES 2582646T3
- Authority
- ES
- Spain
- Prior art keywords
- weight
- tablet
- coating layer
- tablets
- coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un comprimido recubierto que comprende un núcleo de un comprimido y a) una capa de recubrimiento de sellamiento interior colocada sobre el núcleo del comprimido, que comprende una formulación de un polímero de recubrimiento que comprende un polímero a base de alcohol polivinílico (PVA); b) una segunda capa de recubrimiento colocada sobre el recubrimiento de sellamiento interior del núcleo del comprimido, comprendiendo la segunda capa de recubrimiento saxagliptina o una sal farmacéuticamente aceptable de la misma, y una formulación de un polímero de recubrimiento que comprende un polímero a base de PVA; y c) una capa de recubrimiento protector exterior sobre la segunda capa de recubrimiento del núcleo del comprimido, comprendiendo dicha capa de recubrimiento protector exterior una formulación de una capa de recubrimiento que comprende un polímero a base de PVA.
Description
contiene medicamento) estará presente en una cantidad dentro del intervalo desde aproximadamente 0,25 hasta aproximadamente 70%, preferiblemente desde aproximadamente 1 hasta aproximadamente 50% en peso del comprimido recubierto terminado; dependiendo de la potencia; y la tercera capa de recubrimiento protector exterior y opcionalmente la cuarta capa, cada una estará presente en una cantidad dentro del intervalo desde aproximadamente 1 hasta aproximadamente 10%, preferiblemente desde aproximadamente 1 hasta aproximadamente 5% en peso del comprimido recubierto terminado.
Se exponen a continuación formulaciones preferidas de comprimidos recubiertos de acuerdo con la invención.
- Material Placebo del comprimido
- Intervalo posible %/mg en peso de un comprimido con núcleo de placebo de 200 mg Intervalo posible %/mg en peso de un comprimido con núcleo de placebo de 200 mg
- Agente de carga
- 2 a 95%/4 a 190 mg 10 a 85%/20 a 170 mg
- Lactosa
- 0 a 95%/0 a 190 me 20 a 75%/40 a 150 mg
- Celulosa microcristalina
- 0 a 95%/0 a 190 mg 20 a 75%/40 a 150 mg
- Desintegrante
- 0 a 20%/0 a 40 mg 0,25 a 10%/0,5 a 20 mg
- Croscarmelosa de sodio
- 0 a 20%/0 a 40 mg 2 a 10%/4 a 20 mg
- Lubricante
- 0,1 a 5%/0,2 a 10 mg 0,2 a 2%/0,4 a 4 mg
- Estearato de magnesio
- 0,1 a 5%/0,2 a 10 mg 0,2 a 2%/0,4 a 4 mg
- Primera capa de recubrimiento de sellamiento interior
- %/mg en peso de un comprimido con núcleo de placebo de 200 mg %/mg en peso de un comprimido con núcleo de placebo de 200 mg
- Polímero de recubrimiento, y plastificantes y deslizantes opcionales
- 0,5 a 50%/1 a 100 mg 1 a 3%/2 a 6 mg
- Segunda capa de recubrimiento
- %/mg en peso de un comprimido con núcleo de placebo de 200 mg %/mg en peso de un comprimido con núcleo de placebo de 200 mg
- Inhibidor de DPP4 (base libre o sal HCl)
- 0,1 a 70%/0,2 a 140 mg 1 a 50%/2 a 100 mg
- Polímero de recubrimiento, y plastificantes y deslizantes opcionales
- 1 a 70%/2 a 140 mg 1 a 50%/2 a 100 mg
- Tercera capa de recubrimiento protector exterior
- %/mg en peso de un comprimido con núcleo de placebo de 200 mg %/mg en peso de un comprimido con núcleo de placebo de 200 mg
- Polímero de recubrimiento, y plastificantes, deslizantes y color
- 0,5 a 50%/1 a 100 mg 1 a 5%/2 a 10 mg
8
- Tercera capa de recubrimiento protector exterior
- %/mg en peso de un comprimido con núcleo de placebo de 200 mg %/mg en peso de un comprimido con núcleo de placebo de 200 mg
- opcionales
-
imagen7 imagen8
Los siguientes Ejemplos de trabajo representan una realización preferida de la invención.
Se preparó un lote de 500 g de comprimidos recubiertos con DPP4 de 2,5 mg que tienen la siguiente composición como se describe a continuación.
- Núcleo de la tableta
- Peso (mg) % en peso de un comprimido con núcleo de placebo de 200 mg
- Lactosa Monohidratada NF
- 99 mg (49.5%)
- Celulosa microcristalina NF
- 90 mg (45%)
- Croscarmelosa de sodio NF
- 10 mg (5%)
- Estearato de magnesio NF
- 1 mg (0,5%)
- Total
- 200 mg (100,0%)
- imagen9
-
imagen10
- Capa de recubrimiento de sellamiento interior
- 4 mg (2%)
- Opadry® HP que contiene los siguientes ingredientes
-
imagen11
- Alcohol polivinílico 40%
-
imagen12
- PEG 20%
-
imagen13
- Talco 15%
-
imagen14
- Dióxido de titanio 25%
-
imagen15
- imagen16
-
imagen17
- Capa intermedia
-
imagen18
- DPP4-inhibitor, Saxagliptina
- 2,5 mg (1,25%)
- Opadry® HP
- 20 mg (10%)
9
5
10
15
20
25
30
35
40
Se recubrieron los 30 comprimidos con la suspensión de recubrimiento de sellamiento interior como se preparó anteriormente empleando la máquina de recubrimiento Glatt.
Se pesaron los 30 comprimidos cada 10 minutos (y se registró el peso) hasta que el peso del comprimido alcanzó el peso objetivo (Ecuación 1). Las comprimidos recubiertos se secaron por calentamiento hasta que el peso del comprimido se hizo constante. El peso final de las comprimidos recubiertos se designó como B.
Ecuación 1:
Peso objetivo: A x 1,02 = B
Capa de recubrimiento intermedia (Fármaco)
Se preparó la suspensión de la capa de recubrimiento que contiene en el medio el fármaco de la siguiente forma.
Se agregaron 12,5 g del inhibidor de DPP4 saxagliptina (base libre) a 1000 ml de HCl 0,1 N en un recipiente metálico. Se midió el pH y se ajustó a 2. Se agitó continuamente el HCI y se agregó rápidamente 100 g de Opadry® HP en el vórtice. Se agitó luego la mezcla a baja velocidad hasta que fue visualmente evidente una mezcla uniforme. Se mantuvo el pH de la suspensión en 2 usando ya sea HCl concentrado o HCl 1 N según sea necesario.
Se recubrieron los núcleos de los comprimidos recubiertos y sellados preparados anteriormente con la suspensión de recubrimiento que contiene al inhibidor de DPP4 preparado anteriormente, empleando la máquina de recubrimiento Glatt. Se pesaron los 30 comprimidos recubiertos y sellados, inicialmente cada 30 minutos, después cada 15 minutos y se registró el peso hasta que se alcanzó el peso objetivo (Ecuación 2). Los comprimidos así recubiertos se secaron por calentamiento hasta que el peso del comprimido se hizo constante. El peso final de los 30 comprimidos se designó como C.
Ecuación 2:
Peso objetivo: B + 30 x (2,925 (equivalente a 2,5 mg de base libre) + 20 mg): B + 687,75 mg = C
Se determinó la cantidad del fármaco recubierto sobre los comprimidos usando HPLC, sonda de fibra óptica o NIR u otros medios adecuados. Se detuvo el recubrimiento cuando se depositó la cantidad objetivo de fármaco.
Capa de recubrimiento protectora externa
Las comprimidos así recubiertos fueron luego recubiertos con una suspensión de Opadry© HP como se usó en la formación del recubrimiento de sellamiento interior. Se pesaron los 30 comprimidos cada 10 minutos y se registró el peso hasta que el peso de comprimido alcanzó el peso objetivo (Ecuación 3). Los comprimidos se secaron por calentamiento hasta que el peso del comprimido se hizo constante.
El peso final de 30 comprimidos se designó como D.
Ecuación 3:
Peso objetivo = C +30 x4 mg= C + 120 mg = D
Los comprimidos así recubiertos se transfirieron a un recipiente adecuado.
Los comprimidos de la invención así preparados tenían una estabilidad superior para las formulaciones convencionales de comprimidos (en donde el fármaco estaba en el núcleo) y formulaciones en cápsula.
Los anteriores comprimidos recubiertos con potencia de 2,5 mg de la invención, se almacenaron bajo diversas condiciones de almacenamiento y que incluyen 41 semanas y se recolectaron los datos de estabilidad relacionados con la presencia de la amidina cíclica degradante (principalmente amidina cis-cíclica (Cis-CA)). Como se muestra en la Tabla 1 a continuación, no se detectó cis-CA en condiciones de almacenamiento de 25ºC/60% de humedad relativa. Los niveles de cis-CA fueron 0,22% y 0,32% a 30ºC/60% de humedad relativa y 40ºC/75% de humedad relativa en condiciones de almacenamiento, respectivamente. Estos niveles son significantemente menores que aquellos observados en las formulaciones de cápsulas de potencia de 5 mg y 20 mg mostradas en la Tabla 2.
11
0 0 0 0 0 Cápsula de 20 mg
- 41 semanas para todas las condiciones cerradas
- % cis-CA
- % Trans-CA % de amida % cis-CA % Trans-CA
- 0
- 0
- 0
- 0
- 0
- 0
- 0
- 0,03
- 0
- 0
- 0,22
- 0 0,03 0,17 0
- 0,32
- 0 0,03 0,90 0
- 1,00
- 0 0 1,62 0
- NA
- NA
- NA
- NA
- NA
- NA
- NA
- NA
- NA
- NA
13 semanas
% de Cis-CA
0,05
0,14
0,26
0,46
0,43
1,19
26 semanas
% de Cis-CA
0,26
0,62
NA
Claims (1)
-
imagen1 imagen2 imagen3
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57531904P | 2004-05-28 | 2004-05-28 | |
US575319P | 2004-05-28 | ||
PCT/US2005/018692 WO2005117841A1 (en) | 2004-05-28 | 2005-05-26 | Coated tablet formulation and method |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2582646T3 true ES2582646T3 (es) | 2016-09-14 |
ES2582646T5 ES2582646T5 (es) | 2020-03-30 |
Family
ID=34971747
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10179007T Active ES2593582T5 (es) | 2004-05-28 | 2005-05-26 | Formulación de comprimido recubierto y método |
ES05756474T Active ES2582646T5 (es) | 2004-05-28 | 2005-05-26 | Formulación de comprimido recubierto y método |
ES16166031T Active ES2754573T3 (es) | 2004-05-28 | 2005-05-26 | Formulación de comprimido recubierto y método |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10179007T Active ES2593582T5 (es) | 2004-05-28 | 2005-05-26 | Formulación de comprimido recubierto y método |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES16166031T Active ES2754573T3 (es) | 2004-05-28 | 2005-05-26 | Formulación de comprimido recubierto y método |
Country Status (33)
Country | Link |
---|---|
US (4) | US7951400B2 (es) |
EP (3) | EP1753406B2 (es) |
JP (1) | JP4901727B2 (es) |
KR (2) | KR20120064141A (es) |
CN (2) | CN102895208B (es) |
AR (2) | AR049062A1 (es) |
AU (1) | AU2005249467B2 (es) |
BR (1) | BRPI0510419B8 (es) |
CA (1) | CA2568391C (es) |
CY (2) | CY1117813T1 (es) |
DK (2) | DK1753406T4 (es) |
ES (3) | ES2593582T5 (es) |
GE (1) | GEP20094639B (es) |
HK (2) | HK1094951A1 (es) |
HR (2) | HRP20160880T4 (es) |
HU (2) | HUE029446T2 (es) |
IL (2) | IL179454A (es) |
LT (1) | LT2298288T (es) |
ME (2) | ME02643B (es) |
MX (1) | MXPA06013711A (es) |
MY (1) | MY147639A (es) |
NO (1) | NO343907B1 (es) |
NZ (1) | NZ551591A (es) |
PE (1) | PE20060425A1 (es) |
PL (2) | PL1753406T5 (es) |
PT (2) | PT1753406E (es) |
RS (2) | RS55174B2 (es) |
RU (1) | RU2372894C2 (es) |
SI (3) | SI1753406T2 (es) |
TW (2) | TWI354569B (es) |
UA (1) | UA88168C2 (es) |
WO (1) | WO2005117841A1 (es) |
ZA (1) | ZA200609541B (es) |
Families Citing this family (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0487425A (ja) * | 1990-07-31 | 1992-03-19 | Fujitsu Ltd | 回線切り替え装置 |
DK1368349T3 (da) * | 2001-02-24 | 2007-05-21 | Boehringer Ingelheim Pharma | Xanthinderivater, deres fremstilling og deres anvendelse som lægemidler |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
BRPI0506622A (pt) * | 2004-02-05 | 2007-05-02 | Kyorin Seiyaku Kk | éster biciclo derivado; um intermediário na produção do éster biciclo derivado; produto farmacêutico contendo um ingrediente ativo do éster biciclo derivado; inibidor dpp-iv contendo um ingrediente ativo do éster biciclo derivado; agente terapêutico para uma doença envolvendo dpp-iv contendo um ingrediente ativo do éster biciclo derivado, e agente terapêutico |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
TW200534879A (en) * | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
US7829720B2 (en) * | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
TWI354569B (en) | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
GB0526291D0 (en) * | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
JP2009526047A (ja) * | 2006-02-09 | 2009-07-16 | テバ ファーマシューティカル インダストリーズ リミティド | モンテルカストナトリウムの安定な医薬製剤 |
CA2645154C (en) * | 2006-03-08 | 2011-11-29 | Kyorin Pharmaceutical Co., Ltd. | Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof |
CN107235980A (zh) | 2006-05-04 | 2017-10-10 | 勃林格殷格翰国际有限公司 | 多晶型 |
EP1852108A1 (en) * | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
US20070172525A1 (en) * | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
AR065809A1 (es) | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
EP2123636B1 (en) * | 2007-03-22 | 2012-03-21 | Kyorin Pharmaceutical Co., Ltd. | Method for producing aminoacetylpyrrolidinecarbonitrile derivative |
PE20090696A1 (es) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
PL2170292T3 (pl) * | 2007-06-22 | 2014-06-30 | Bristol Myers Squibb Holdings Ireland | Tabletkowane kompozycje zawierające atazanawir |
JP2010530889A (ja) * | 2007-06-22 | 2010-09-16 | ブリストル−マイヤーズ スクイブ カンパニー | アタザナビルを含む錠剤組成物 |
US20100178340A1 (en) * | 2007-06-22 | 2010-07-15 | Bristol-Myers Squibb Company | Tableted compositions containing atazanavir |
JP2010530892A (ja) * | 2007-06-22 | 2010-09-16 | ブリストル−マイヤーズ スクイブ カンパニー | アタザナビルを含む錠剤組成物 |
WO2009015880A1 (en) * | 2007-07-31 | 2009-02-05 | Cargill, Incorporated | Direct compressible dextrose |
JP5965583B2 (ja) * | 2007-08-13 | 2016-08-10 | インスピリオン デリバリー テクノロジーズ エルエルシー | 乱用抵抗性医薬組成物、その使用方法および作製方法 |
WO2010019279A1 (en) * | 2008-08-12 | 2010-02-18 | Abuse Deterrent Pharmaceutical Llc | Pharmaceutical compositions configured to deter dosage form splitting |
CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
US8551524B2 (en) * | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
IT1393244B1 (it) * | 2008-07-18 | 2012-04-12 | Universita' Degli Studi Di Milano | Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale |
KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
US8476470B2 (en) * | 2008-08-07 | 2013-07-02 | Kyorin Pharmaceutical Co., Ltd. | Process for production of bicyclo[2.2.2]octylamine derivative |
US20110152342A1 (en) * | 2008-08-14 | 2011-06-23 | Hiroshi Uchida | Stabilized pharmaceutical composition |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
DE102008059206A1 (de) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
UY32048A (es) | 2009-01-08 | 2010-03-26 | Boehringer Ingelheim Int | Derivados sustituido de 1-(sustituido)-3-metil-7-(sustituido)-8-(3-(R)-amino-piperidin-1-il)cantina y derivados sustituidos de 1-(sustituido) - 4 - fluoropirrolidin- 2 - carbonitrilo y sus sales famacéuticamente aceptables como inhibidores de DPP-4 y aplicaciones. |
AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
MA33046B1 (fr) | 2009-02-13 | 2012-02-01 | Boehringer Ingelheim Int | Composition pharmaceutique contenant un inhibiteur sglt-2, un inhibiteur dpp- iv et facultativemenet un autre agent antidiabetique et ses utilisations |
US20120094894A1 (en) | 2009-02-13 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
KR20120003906A (ko) | 2009-03-27 | 2012-01-11 | 교린 세이야꾸 가부시키 가이샤 | 염기성 첨가제를 함유하는 매트릭스형 서방성 제제 |
US20100256153A1 (en) | 2009-03-27 | 2010-10-07 | Bristol-Myers Squibb Company | Methods for preventing or reducing risk of mortality |
KR20120006047A (ko) | 2009-04-09 | 2012-01-17 | 산도즈 아게 | 삭사글립틴의 결정 형태 |
JP5784623B2 (ja) | 2009-11-13 | 2015-09-24 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | 速放性錠剤製剤 |
WO2011060256A2 (en) | 2009-11-13 | 2011-05-19 | Bristol-Myers Squibb Company | Bilayer tablet formulations |
ES2760917T3 (es) | 2009-11-27 | 2020-05-18 | Boehringer Ingelheim Int | Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
CN102210693B (zh) * | 2010-04-10 | 2013-10-09 | 山东新华制药股份有限公司 | 一种阿司匹林和双嘧达莫多层片的制备方法 |
WO2011140328A1 (en) | 2010-05-05 | 2011-11-10 | Teva Pharmaceutical Industries Ltd. | Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof |
BR112012028136A2 (pt) | 2010-05-05 | 2016-08-09 | Boehringer Ingelheim Int | terapia de combinaçao |
ES2953123T3 (es) | 2010-06-24 | 2023-11-08 | Boehringer Ingelheim Int | Terapia para la diabetes |
EP2601176A1 (en) | 2010-08-06 | 2013-06-12 | Sandoz AG | Novel salts of saxagrliptin with organic di-acids |
WO2012017028A1 (en) | 2010-08-06 | 2012-02-09 | Sandoz Ag | A novel crystalline compound comprising saxagliptin and phosphoric acid |
MX2013002146A (es) | 2010-09-03 | 2013-04-03 | Astrazeneca Uk Ltd | Formulaciones farmaceuticas que utilizan antioxidantes solubles en agua. |
US8410288B2 (en) | 2010-10-04 | 2013-04-02 | Teva Pharmaceutical Industries Ltd. | Polymorphs of Saxagliptin hydrochloride and processes for preparing them |
EP2637668B1 (en) | 2010-11-08 | 2016-05-11 | Albireo AB | Ibat inhibitors for the treatment of liver diseases |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
CN102086172A (zh) * | 2011-01-13 | 2011-06-08 | 廖国超 | 沙格列汀的药用盐及其制备方法 |
EP2670397B1 (en) * | 2011-02-01 | 2020-05-13 | Bristol-Myers Squibb Company | Pharmaceutical formulations including an amine compound |
ES2713566T3 (es) | 2011-07-15 | 2019-05-22 | Boehringer Ingelheim Int | Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II |
RU2014109074A (ru) | 2011-08-12 | 2015-09-20 | Бёрингер Ингельхайм Ветмедика Гмбх | ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ |
EA201490556A1 (ru) | 2011-09-07 | 2014-08-29 | Сановел Илач Санайи Ве Тиджарет Аноним Ширкети | Составы ингибитора дпп-4 |
US9446000B2 (en) | 2011-09-08 | 2016-09-20 | Masdar Institute Of Science And Technology | Cellulosic gel material as a pharmaceutical excipient |
ES2487271T3 (es) | 2011-10-06 | 2014-08-20 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Formulaciones de dosificación sólidas inhibidoras de DPP-IV |
US20130189358A1 (en) | 2012-01-10 | 2013-07-25 | Roey Solomonovich | Saxagliptin pharmaceutical formulations |
US10973768B2 (en) | 2012-03-01 | 2021-04-13 | Bristol-Myers Squibb Company | Extended release pharmaceutical formulations of water-soluble active pharmaceutical ingredients and methods for making the same |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
CN104507459A (zh) | 2012-05-07 | 2015-04-08 | 拜耳制药股份公司 | 包含硝苯地平和坎地沙坦酯的药物剂型的制造方法 |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2013179307A2 (en) * | 2012-05-29 | 2013-12-05 | Mylan Laboratories Limited | Stabilized pharmaceutical compositions of saxagliptin |
WO2014030051A1 (en) | 2012-08-23 | 2014-02-27 | Aurobindo Pharma Limited | Stable pharmaceutical compositions comprising saxagliptin |
JP6283316B2 (ja) * | 2012-10-26 | 2018-02-21 | 株式会社三和化学研究所 | アナグリプチン含有固形製剤 |
WO2014096983A1 (en) | 2012-12-21 | 2014-06-26 | Wockhardt Limited | Stable pharmaceutical compositions of saxagliptin or salts thereof |
WO2014096982A1 (en) | 2012-12-21 | 2014-06-26 | Wockhardt Limited | Stable pharmaceutical compositions of saxagliptin or salts thereof |
CA2907428A1 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
WO2014193528A1 (en) * | 2013-04-29 | 2014-12-04 | Anovel Pharmaceuticals, Llc | Amorphous dosage forms and methods |
CN103316056B (zh) * | 2013-06-24 | 2015-07-08 | 江苏鹏鹞药业有限公司 | 一种板蓝根包衣分散片及其制备方法 |
WO2015071887A1 (en) | 2013-11-18 | 2015-05-21 | Ranbaxy Laboratories Limited | Oral pharmaceutical compositions of saxagliptin |
WO2015071889A1 (en) | 2013-11-18 | 2015-05-21 | Ranbaxy Laboratories Limited | Oral compositions of saxagliptin |
PL3096891T3 (pl) | 2014-01-21 | 2020-08-24 | Bpsi Holdings, Llc. | Otoczki o natychmiastowym uwalnianiu zawierające glicerydy średniołańcuchowe oraz powlekane nimi rdzenie |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
JP6751020B2 (ja) * | 2014-06-25 | 2020-09-02 | Eaファーマ株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
CN105520913B (zh) * | 2014-09-28 | 2020-06-23 | 石药集团中奇制药技术(石家庄)有限公司 | 一种包含沙格列汀的微丸、其用途及其制备方法 |
CN105497023B (zh) * | 2014-10-15 | 2021-05-25 | 北京福元医药股份有限公司 | 一种沙格列汀药物制剂 |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
CN104557943B (zh) * | 2014-12-23 | 2017-05-03 | 扬子江药业集团四川海蓉药业有限公司 | 一种维格列汀杂质的制备方法 |
CN105796503B (zh) * | 2014-12-30 | 2019-05-07 | 深圳翰宇药业股份有限公司 | 一种沙格列汀微丸及其制剂 |
CN104672243B (zh) * | 2015-02-10 | 2017-09-22 | 华润赛科药业有限责任公司 | 维格列汀降解杂质的制备方法 |
SI3277278T1 (sl) | 2015-04-02 | 2020-04-30 | Theravance Biopharma R&D Ip, Llc | Kombinacijska odmerna oblika mu-opioidnega receptorskega antagonista in opioidnega sredstva |
CN106176661B (zh) * | 2015-04-29 | 2019-02-01 | 四川科伦药物研究院有限公司 | 一种沙格列汀或其盐的胶囊及其制备方法 |
PL3881833T3 (pl) * | 2015-06-30 | 2024-05-13 | Genentech, Inc. | Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek |
CN106924207A (zh) * | 2015-12-31 | 2017-07-07 | 深圳翰宇药业股份有限公司 | 一种维格列汀片剂及其制备方法 |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
JP2020530448A (ja) | 2017-08-09 | 2020-10-22 | アルビレオ・アクチボラグ | コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用 |
CN108822820B (zh) * | 2018-05-22 | 2020-11-03 | 东莞理工学院 | 一种隔离型水合物动力学抑制胶囊及其制备方法与应用 |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
WO2019234077A1 (en) | 2018-06-05 | 2019-12-12 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
CA3100691A1 (en) | 2018-06-20 | 2019-12-26 | Albireo Ab | Crystal modifications of odevixibat |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
WO2020098904A1 (en) | 2018-11-12 | 2020-05-22 | Pharmaceutical Oriented Services Ltd | Dosage form containing metformin and a dipeptidyl peptidase iv inhibitor |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
CN109999006A (zh) * | 2019-04-28 | 2019-07-12 | 江苏豪森药业集团有限公司 | 沙格列汀包衣片及其制备方法 |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
EP4069359B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
IL293379A (en) | 2019-12-04 | 2022-07-01 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
ES2973355T3 (es) | 2019-12-04 | 2024-06-19 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
JP2023504644A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
JP7514121B2 (ja) | 2020-06-23 | 2024-07-10 | 沢井製薬株式会社 | サキサグリプチン含有製剤及びその製造方法 |
CN116157389A (zh) | 2020-08-03 | 2023-05-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
KR20230106651A (ko) | 2020-11-12 | 2023-07-13 | 알비레오 에이비 | 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트 |
JP2024500309A (ja) | 2020-12-04 | 2024-01-09 | アルビレオ エービー | ベンゾチア(ジ)アゼピン化合物および胆汁酸モジュレータとしてのその使用 |
KR20220165346A (ko) | 2021-06-08 | 2022-12-15 | 동아에스티 주식회사 | 에보글립틴의 안정성이 개선된 제제 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3696188A (en) * | 1971-06-16 | 1972-10-03 | Schering Corp | Laminated tablets |
DE3403329A1 (de) * | 1984-02-01 | 1985-08-01 | Horst Dr. 4019 Monheim Zerbe | Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe |
JPS6186211A (ja) | 1984-10-04 | 1986-05-01 | 日本碍子株式会社 | セラミックス複合構造体及びその製造法 |
FR2623810B2 (fr) * | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
US5158777A (en) * | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
CA2068402C (en) * | 1991-06-14 | 1998-09-22 | Michael R. Hoy | Taste mask coatings for preparation of chewable pharmaceutical tablets |
US5428048A (en) | 1993-11-08 | 1995-06-27 | American Home Products Corporation | Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents |
GB9407386D0 (en) * | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
TW522014B (en) | 1997-02-07 | 2003-03-01 | Sepracor Inc | Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine |
GB9715896D0 (en) | 1997-07-28 | 1997-10-01 | Sca Packaging Ltd | Containers |
US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
US20010055613A1 (en) * | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
JP2002540102A (ja) * | 1999-03-22 | 2002-11-26 | ブリストル−マイヤーズ スクイブ カンパニー | cGMPホスホジエステラーゼの縮合ピリドピリダジン阻害剤 |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
WO2001034148A1 (fr) | 1999-11-11 | 2001-05-17 | Kyorin Pharmaceutical Co., Ltd. | Preparations solides pour administration orale |
US6569456B2 (en) * | 2000-01-13 | 2003-05-27 | Osmotica Corp. | Osmotic device containing diltiazem and an ACE inhibitor or diuretic |
US20030139434A1 (en) | 2000-01-21 | 2003-07-24 | Bork Balkan | Combinations comprising dipeptidylpeptidase-iv inhibitor |
US6254888B1 (en) * | 2000-01-28 | 2001-07-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for coating pharmaceutical dosage forms |
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
US6670344B2 (en) * | 2000-09-14 | 2003-12-30 | Bristol-Myers Squibb Company | Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts |
US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
US6670334B2 (en) | 2001-01-05 | 2003-12-30 | University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
AU2002248792B2 (en) | 2001-04-18 | 2006-09-21 | Nostrum Pharmaceuticals Inc. | A novel coating for a sustained release pharmaceutical composition |
US20030035839A1 (en) * | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
AU2003201071A1 (en) | 2002-01-15 | 2003-07-30 | Ranbaxy Laboratories Limited | Stable pharmaceutical compositions comprising ace inhibitor(s) |
KR100456833B1 (ko) | 2002-08-01 | 2004-11-10 | 주식회사 대웅 | 아목시실린 및 클라불라네이트를 함유하는 유핵정 |
US7670624B2 (en) * | 2004-01-29 | 2010-03-02 | Astella Pharma Inc. | Gastrointestinal-specific multiple drug release system |
TW200534879A (en) * | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
US7829720B2 (en) * | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
US20050288343A1 (en) * | 2004-05-19 | 2005-12-29 | Andrew Rusowicz | Process of preparing substituted carbamates and intermediates thereof |
TWI354569B (en) | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
-
2005
- 2005-05-23 TW TW094116772A patent/TWI354569B/zh not_active IP Right Cessation
- 2005-05-23 TW TW100134799A patent/TWI415635B/zh not_active IP Right Cessation
- 2005-05-25 US US11/137,068 patent/US7951400B2/en active Active
- 2005-05-26 HU HUE10179007A patent/HUE029446T2/en unknown
- 2005-05-26 RS RS20160797A patent/RS55174B2/sr unknown
- 2005-05-26 UA UAA200613939A patent/UA88168C2/uk unknown
- 2005-05-26 PT PT05756474T patent/PT1753406E/pt unknown
- 2005-05-26 MX MXPA06013711A patent/MXPA06013711A/es active IP Right Grant
- 2005-05-26 ES ES10179007T patent/ES2593582T5/es active Active
- 2005-05-26 PT PT101790079T patent/PT2298288T/pt unknown
- 2005-05-26 ES ES05756474T patent/ES2582646T5/es active Active
- 2005-05-26 SI SI200532082T patent/SI1753406T2/sl unknown
- 2005-05-26 MY MYPI20052400A patent/MY147639A/en unknown
- 2005-05-26 EP EP05756474.2A patent/EP1753406B2/en active Active
- 2005-05-26 BR BRPI0510419A patent/BRPI0510419B8/pt active IP Right Grant
- 2005-05-26 KR KR1020127014475A patent/KR20120064141A/ko not_active Application Discontinuation
- 2005-05-26 CN CN201210377942.2A patent/CN102895208B/zh active Active
- 2005-05-26 LT LTEP10179007.9T patent/LT2298288T/lt unknown
- 2005-05-26 RS RS20160563 patent/RS54929B2/sr unknown
- 2005-05-26 SI SI200532097T patent/SI2298288T2/sl unknown
- 2005-05-26 CA CA2568391A patent/CA2568391C/en not_active Expired - Fee Related
- 2005-05-26 ME MEP-2016-213A patent/ME02643B/me unknown
- 2005-05-26 WO PCT/US2005/018692 patent/WO2005117841A1/en active Application Filing
- 2005-05-26 ES ES16166031T patent/ES2754573T3/es active Active
- 2005-05-26 CN CN2005800245879A patent/CN1988891B/zh active Active
- 2005-05-26 ME MEP-2016-145A patent/ME02516B/me unknown
- 2005-05-26 KR KR1020067024818A patent/KR101290925B1/ko active IP Right Grant
- 2005-05-26 EP EP10179007.9A patent/EP2298288B2/en active Active
- 2005-05-26 PL PL05756474T patent/PL1753406T5/pl unknown
- 2005-05-26 AU AU2005249467A patent/AU2005249467B2/en active Active
- 2005-05-26 SI SI200532082A patent/SI1753406T1/sl unknown
- 2005-05-26 GE GEAP20059797A patent/GEP20094639B/en unknown
- 2005-05-26 NZ NZ551591A patent/NZ551591A/en unknown
- 2005-05-26 RU RU2006146971/15A patent/RU2372894C2/ru active
- 2005-05-26 EP EP16166031.1A patent/EP3078369B1/en active Active
- 2005-05-26 DK DK05756474T patent/DK1753406T4/da active
- 2005-05-26 JP JP2007515382A patent/JP4901727B2/ja active Active
- 2005-05-26 PL PL10179007T patent/PL2298288T5/pl unknown
- 2005-05-26 DK DK10179007.9T patent/DK2298288T4/da active
- 2005-05-26 HU HUE05756474A patent/HUE029039T2/en unknown
- 2005-05-27 AR ARP050102188A patent/AR049062A1/es not_active Application Discontinuation
- 2005-05-30 PE PE2005000601A patent/PE20060425A1/es active IP Right Grant
-
2006
- 2006-11-16 ZA ZA2006/09541A patent/ZA200609541B/en unknown
- 2006-11-21 IL IL179454A patent/IL179454A/en active IP Right Grant
- 2006-12-15 NO NO20065870A patent/NO343907B1/no unknown
-
2007
- 2007-03-06 HK HK07102473.5A patent/HK1094951A1/zh active IP Right Maintenance
- 2007-03-06 HK HK11109873.0A patent/HK1155399A1/zh active IP Right Maintenance
-
2011
- 2011-04-26 US US13/094,379 patent/US8628799B2/en active Active
-
2012
- 2012-02-14 IL IL218117A patent/IL218117A/en active IP Right Grant
-
2014
- 2014-01-08 US US14/150,331 patent/US9339472B2/en active Active
- 2014-05-22 US US14/284,840 patent/US20140255486A1/en not_active Abandoned
-
2015
- 2015-02-24 AR ARP150100554A patent/AR099567A2/es unknown
-
2016
- 2016-07-15 HR HRP20160880TT patent/HRP20160880T4/hr unknown
- 2016-07-19 CY CY20161100703T patent/CY1117813T1/el unknown
- 2016-09-21 HR HRP20161210TT patent/HRP20161210T4/hr unknown
- 2016-09-22 CY CY20161100945T patent/CY1118162T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2582646T3 (es) | Formulación de comprimido recubierto y método | |
ES2374690T3 (es) | Comprimidos de liberación retardada con hidromorfona. | |
AU2019201929B2 (en) | Ribociclib tablet | |
AR017747A1 (es) | Perlas farmaceuticas con recubrimiento entcrico, opcionalmente recubiertas con un anti-adherente dispuesto en el exterior de dicho recubrimiento entcrico, y un procedimiento para preparar dichas perlas farmaccuticas con recubrimiento entcrico | |
HRP20190069T1 (hr) | Farmaceutske formulacije koje sadrže ccr3 antagoniste | |
ES2282270T3 (es) | Preparaciones de liberacion retardada a partir de antibioticos quinol onicos y procedimiento para su preparacion. | |
AU2008277444B2 (en) | Stable pharmaceutical compositions comprising one or more HMG-CoA reductase inhibitors | |
ES2349996T3 (es) | Preparado de liberación retardada en forma de pellas que contiene cinarizina y dimenhidrinato contra el vértigo. | |
ES2279715B1 (es) | Formulacion oral de olanzapina. | |
KR101483476B1 (ko) | 의약 고형 제제용의 코팅제, 의약용 필름 제제 및 피복 의약 고형 제제 | |
KR101045508B1 (ko) | 필름 코팅정 | |
US20190224201A1 (en) | Pharmaceutical composition comprising neptinib or salt thereof and method for controlling impurity thereof | |
KR101294921B1 (ko) | 2,3-디히드로-6-니트로이미다조〔2,1-b〕옥사졸 유도체 함유 제약 조성물 | |
CA2963761A1 (en) | Pharmaceutical composition of fused aminodihydrothiazine derivative | |
CA2797458A1 (en) | Tablet formulation of ezatiostat | |
JP6210640B2 (ja) | ホリナートカルシウム含有錠 | |
AU2014284294A1 (en) | Capsule formulation comprising fexofenadine | |
JP2015137238A (ja) | イブプロフェン及びトラネキサム酸を含有するフィルムコーティング製剤 | |
US20120283325A1 (en) | Excipient compatibility with ezatiostat | |
KR102158339B1 (ko) | 인습성이 개선된 카르베딜롤 속방성 제제 | |
JP2009084242A (ja) | 安定性に優れた塩酸テモカプリル錠剤 | |
ES2818249T3 (es) | Composición farmacéutica que comprende un agente antipsicótico atípico y método para su preparación | |
RO129060B1 (ro) | Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă | |
JP2019085425A (ja) | ホリナートカルシウム含有錠 | |
RU2013127408A (ru) | Таблетка с контролируемым высвобождением для перорального введения и способ ее приготовления |